Procaps Group S.A. PROC
1.01 USD 0.00 (+0.00%)
At closeMar 12, 2026, 4:00 PM EDT
1.01 Day range 1.01
0.50 52-week range 4.95
- YTD
- 0.00%
- 1 year
- 0.00%
News
gurufocus.com Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026 Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026PR NewswireINDI
gurufocus.com /C O R R E C T I O N - AbbVie/ /C O R R E C T I O N - AbbVie/PR NewswireNORTH CHICAGO, Ill., Oct. 18, 2026In the news release, AbbVie to Present Data at the 2026 European Society for Medical
gurufocus.com Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressPR NewswireINDIANAPOLIS, Oct. 18, 2026F
gurufocus.com AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor PortfolioPR News
gurufocus.com Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer [url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOLâ¢-01 trial evaluating rinatabart sesutecan (Rina-S), an inv
defenseworld.net ProCook Group (LON:PROC) Trading Up 5.9% – Should You Buy? ProCook Group plc (LON: PROC - Get Free Report)'s share price was up 5.9% on Wednesday. The company traded as high as GBX 36 and last traded at GBX 36. Approximately 58 shares changed hands during…
globenewswire.com Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject…
globenewswire.com Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership New Investors Take Over the Strategic Leadership as Headquarters Move to Bogotá, Marking the Start of a New Chapter of Growth, Execution, and Transformation under Enhanced Governance
seekingalpha.com Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day.…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
globenewswire.com Procaps Group Receives Delisting Notice From Nasdaq MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services…
globenewswire.com Procaps Group Receives Additional Delinquency Letter MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
globenewswire.com Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services…
globenewswire.com Procaps Group Announces Financing, Shareholders Agreement and Board Updates MIAMI and BARRANQUILLA, Colombia , Dec. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services…
benzinga.com Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket 
globenewswire.com Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), announced today that, on November 13, 2024, the Company received…
globenewswire.com Procaps Issues Shareholder Letter Update MIAMI and BARRANQUILLA, Colombia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services,…
globenewswire.com Procaps Issues Shareholder Letter Update MIAMI and BARRANQUILLA, Colombia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical…
globenewswire.com Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024 COPENHAGEN, Denmark, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced initial data showing signs of clinical activity in heavily pre-treated patients with…
globenewswire.com Procaps Issues Shareholder Letter MIAMI and BARRANQUILLA, Colombia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical…
investorplace.com 7 Undervalued Biotech Stocks to Buy for Big-Time Returns Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
https://www.accesswire.com Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and…- benzinga.com Earnings Scheduled For November 14, 2023 Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
benzinga.com Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge…- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday saw 132 companies set new 52-week lows.
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 
benzinga.com Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session.- benzinga.com Earnings Scheduled For November 14, 2022 Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.